HSP90和P23蛋白量和细胞亚定位在多发性骨髓瘤患者中的临床价值

Clinical value of protein content and cell sublocation of HSP90 and P23 in patients with multiple myeloma

目的寻找预测MM患者GC敏感性指标。方法以MM患者作为研究对象,采用ELISA法检测MM患者血清HSP90浓度,Western Blot检测MM患者PBMNC中P23蛋白表达,探讨其与GC抵抗的关系。结果 (1)MM患者血清HSP90含量明显比正常人高(P<0.05),且GC敏感组患者较GC抵抗组患者高(P<0.05),但各组P23血清浓度之间差异无统计学意义(P>0.05);(2)P23蛋白低表达患者和P23蛋白高表达患者治疗有效率分别为86%和33%,二者相比差异具有统计学意义(P<0.05),在5年随访中,前者生存率高于后者(P<0.05);(3)HSP90和P23蛋白在MM1.S、MM1.R细胞株以及GC敏感和抵抗的MM患者均位于胞浆内,无定位意义。结论血清HSP90和P23蛋白表达能预测MM患者对GC的敏感性和生存情况,可用此指标指导临床用药。

Objective To find the predicitive indicators of GC sensitivity in the patients with multiple myeloma （MM）.MethodsThe patients with MM were selected as the study subjects. The ELISA was used to detect the serum heat-shock protein 90 （HSP90） concentraion in the patients with MM and the Western Blot was used to detect the P23 protein expression in PBMNC in the patients with MM, and their relationship with GC resistance was explored. Results （1） The patients with MM had significantly higher HSP90 content than normal people （P〈0.05）, and the GC sensitive group was higher than the GC resistant group （P〈0.05）, but the P23 serum concentration was not different between each group （P〉0.05）; （2） The effective treatment rates of the patients with low P23 protein expression and the patietns with high P23 protein expression were 86% and 33% respectively, with significant difference between the two groups （P〈0.05）, and in the 5-year follow-up visit, the former had higher survival rate than the latter （P〈0.05）; （3） Both HSP90 and P23 protein existed in the cytoplasm of MM1.S and MM1.R cell strains as well as the the patients with MM who were sensitive and resistant to GC, and had no locating value.Conclusion Serum HSP90 and P23 protein expression can predict the MM patients＆#39; sensitivity to GC and survival situation, thus can be used to guide clinical drug use.